12月15日晚，一品红（300723.SZ）发布公告表示，拟出售参股公司美国Arthrosi Therapeutics, Inc.（以 下简称Arthrosi）公司股权。目前一品红通过全资子公司瑞騰生物(香港)有限公司持有Arthrosi 13.45%的 股权。 根据公告，近日，Arthrosi拟与瑞典 Swedish Orphan Biovitrum AB (pub1)下属全资子公司Sobi US Holding Corp.(以下简称Sobi美国)签署并购协议，Sobi美国拟以9.5亿美元首付款(折合人民币约67.13亿 元)，以及最高达5.5亿美元（折合人民币约38.87亿元）的临床、注册和销售里程碑付款收购Arthrosi公 司100%股权。 上述交易需Arthrosi股东会批准，交易完成后，一品红将不再持有Arthrosi股权。根据Arthrosi公司章程， Arthrosi公司被合并事项应获得有表决权的已发行股份过半数股东的同意，以及Arthrosi公司E轮次代表 超过75%表决权的优先股股东同意。相关交易事项能否实施，最终交易对价以及交易完成时间均存在不 确定性。 而本次并购的核心标的是Arthr ...

近日，一品红（300723）药业集团股份有限公司（简称"一品红"）发布公告称，公司及子公司广州一品 红制药有限公司（简称"一品红制药"）等多家主体因知识产权纠纷被汇友国际有限公司（简称"汇友国 际"）起诉，涉案金额合计5.286亿元。一品红曾因在国家药品集采中的违规行为引发巨额医保退款，随 后业绩便由盈转亏，这家深耕医药领域20余年的企业正面临多重挑战。 十年前合作引发纠纷 这场诉讼可溯至2014年。公告显示，2014年10月31日，一品红制药与汇友国际就注射用前列地尔脂质体 合作事宜签署《合作协议》，约定双方共同现金出资1000万元设立合资公司广州市品瑞医药科技有限公 司（简称"品瑞医药"）。一品红制药持有合资公司52%股权、汇友国际持有48%股权，并由品瑞医药推 进前列地尔的研发。 协议约定，汇友国际将注射用前列地尔脂质体有关的专利（专利号为ZL200510110924.8）和技术秘密全 部注入品瑞医药并由品瑞医药提供给一品红制药使用。专利完成转让后，一品红制药向汇友国际及其相 关方支付1500万元，待取得生产批件后再支付3000万元。 一品红称，一品红制药已于2015年-2016年按协议支付了1500万 ...

Core Viewpoint - Recently, Huayou International Ltd. has filed a lawsuit against Yipin Hong Pharmaceutical Co., Ltd. regarding intellectual property disputes, claiming ownership of several patents related to a specific injection formulation and seeking substantial damages [2][3]. Group 1: Lawsuit Details - The lawsuit requests confirmation of ownership of multiple patents for "an injection formulation of prostaglandin E1 and its preparation method" and demands the defendants to cease infringement, along with a compensation claim of 528 million yuan and legal fees of 600,000 yuan [2][3]. - The background of the lawsuit traces back to a cooperation agreement signed on October 31, 2014, where Yipin Hong Pharmaceutical and Huayou International established a joint venture, with Yipin holding 52% and Huayou 48% of the shares [3][4]. Group 2: Financial Performance - For the first three quarters of 2025, Yipin Hong reported revenues of 814 million yuan, a year-on-year decline of 34.35%, and a net loss attributable to shareholders of 136 million yuan, compared to a loss of 247 million yuan in the same period last year [6][7]. - In 2024, Yipin Hong's total revenue was 1.45 billion yuan, down 42.07%, with a net loss of 540 million yuan, contrasting with a profit of 185 million yuan in the previous year [6][7]. Group 3: Regulatory Issues - In August 2024, Yipin Hong's subsidiary was disqualified from participating in the centralized procurement of a specific injection due to violations of procurement regulations, which significantly impacted its revenue from that product [6][7]. - The company has taken corrective measures, including returning medical insurance funds and lowering the price of the affected injection, while its participation in centralized procurement was suspended for six months [7]. Group 4: Future Outlook - Yipin Hong has set performance targets for 2025, including a profit growth rate of no less than 32% compared to 2023, the approval of at least one new innovative drug IND, and obtaining no fewer than 10 drug registration approvals [8]. - As of the mid-2025 report, the company has already achieved significant progress, having received 10 drug registration approvals for 9 self-developed projects [9].

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. is facing a lawsuit from Huiyou International Ltd. regarding intellectual property disputes, with the claimed amount being 528.6 million yuan [2][3] Group 1: Lawsuit Details - The lawsuit was filed in the Guangdong High People's Court, and the case has been accepted but not yet heard [2] - The dispute traces back to a cooperation agreement signed in October 2014, where Yipinhong's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., and Huiyou International agreed to establish a joint venture, Guangzhou Pinrui Pharmaceutical Technology Co., Ltd. [2] - The joint venture was established with a cash investment of 10 million yuan, with Yipinhong holding 52% and Huiyou holding 48% [2] Group 2: Claims and Counterclaims - Huiyou International claims that the original valuation of the intellectual property injected into the joint venture was 88 million yuan, leading to a compensation request of 528 million yuan, which is six times the original valuation [3] - The lawsuit requests the defendants to cease infringement on specific patents and to transfer ownership of another patent to Huiyou International [3] Group 3: Company Response - Yipinhong asserts that it has complied with the agreement by paying 15 million yuan in 2015-2016 and denies any breach of contract [4] - The company has engaged a legal team to analyze the lawsuit and believes that the claims made by Huiyou International should be dismissed [4] - Yipinhong emphasizes that the lawsuit will not impact its daily operations or research and development [4] Group 4: Financial Performance - For the first three quarters of 2025, Yipinhong reported revenue of 814 million yuan, a year-on-year decrease of 34.35%, and a net profit of 136 million yuan, with losses narrowing by 44.80% year-on-year [5] - As of the announcement date, Yipinhong and its subsidiaries have other undisclosed litigation matters totaling 5.6312 million yuan, with no claims as a plaintiff [5]

Core Viewpoint - Recently, Yipin Hong announced that Huiyou International Limited has filed a lawsuit against Yipin Hong Pharmaceutical Co., Ltd. and related parties over a patent dispute, claiming ownership of a specific patent and seeking compensation of 528 million yuan and reasonable legal fees of 600,000 yuan [1][2]. Summary by Sections Legal Action - Huiyou International has initiated legal proceedings against Yipin Hong Pharmaceutical, Yipin Hong Pharmaceutical Group, and several associated companies and individuals, including Chairman Li Huanxiong [1]. - The lawsuit has not yet been heard in court as of the announcement date [1]. Patent and Financial Claims - The plaintiff, Huiyou International, is seeking to confirm ownership of a patent and is claiming a total of 528 million yuan in damages, which is six times the original estimated value of the patent at 88 million yuan [2]. - The lawsuit also includes a request for 600,000 yuan in reasonable legal fees [1][2]. Background of the Cooperation Agreement - In October 2014, Yipin Hong Pharmaceutical and Huiyou International signed a cooperation agreement to establish a joint venture, Guangzhou Pinrui Pharmaceutical Technology Co., Ltd., with Yipin Hong holding 52% and Huiyou International holding 48% of the shares [1]. - The agreement stipulated that Huiyou International would transfer all relevant patents and trade secrets related to the injectable prostaglandin lipid microspheres to the joint venture, which would then provide these to Yipin Hong for use [2]. - Yipin Hong has already paid 15 million yuan to Huiyou International as part of the agreement and is required to pay an additional 30 million yuan upon obtaining production approval for the lipid microspheres [2].